Workshop: Therapeutic and Clinical implications of the genomic landscape of breast cancer
The Campus Bio-Medico University Hospital offers molecular tests aimed at personalizing the therapeutic path of patients with cancer, the PROSIGN test. PROSIGNA is a molecular test (CE-IVD and FDA approved) useful for defining the risk of recurrence of metastatic disease ten years after surgery in women operated on for hormone-sensitive postmenopausal breast cancer. The test investigates the expression profile of a group of 50 genes known as PAM50. The pool of genes analyzed also makes it possible to classify breast cancer into the various molecular subtypes, providing more information to establish the most suitable therapeutic pathway.
Learning outcomes: illustrate the rational, scientific and clinical basis of the molecular classification of breast cancer through the use of the Prosigna Test. The preliminary results of the clinical trial "PAM50/Ki67" - Campus Bio-Medico University Hospital will be presented.
Scientific director: Prof. Giuseppe Tonini
Recipients: The course is aimed at oncologists, pathologists, surgeons, radiotherapists for a total of 70 participants.
Enrolment deadline: June 4, 2015.
>> For more information, click here.
